Trial Profile
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Mar 2018
Price :
$35
*
At a glance
- Drugs Bitopertin (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms DAYLYTE
- Sponsors Roche
- 31 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Apr 2014 Planned End Date changed from 1 Jan 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.
- 21 Jan 2014 Top-line results published in a Roche media release.